GDNF-secreting mesenchymal stem cells provide localized neuroprotection in an inflammation-driven rat model of Parkinson's disease

Neuroscience

Volumn 303, Issue , 2015, Pages 402-411

  Hoban, D B ^a   Howard, L ^a   Dowd, E ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

GDNF; Inflammation; Lipopolysaccharide; Mesenchymal stem cells; Neuroprotection; Parkinson's disease

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; CD11B ANTIGEN; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; LIPOPOLYSACCHARIDE; NEUROPROTECTIVE AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EX VIVO GENE TRANSFER; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SUBSTANTIA NIGRA; ANIMAL; DISEASE MODEL; DRUG EFFECTS; FORELIMB; GENETIC TRANSDUCTION; GENETICS; HEMISPHERIC DOMINANCE; INNERVATION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT; TIME FACTOR; TRANSGENIC RAT; VIBRISSA;

ANIMALS; ANTIGENS, CD11B; DISEASE MODELS, ANIMAL; FORELIMB; FUNCTIONAL LATERALITY; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GREEN FLUORESCENT PROTEINS; LIPOPOLYSACCHARIDES; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; SUBSTANTIA NIGRA; TIME FACTORS; TRANSDUCTION, GENETIC; VIBRISSAE;

EID: 84937390053     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2015.07.014     Document Type: Article

References (56)

1. Aoi M., Date I., Tomita S., Ohmoto T. Single administration of GDNF into the striatum induced protection and repair of the nigrostriatal dopaminergic system in the intrastriatal 6-hydroxydopamine injection model of hemiparkinsonism. Restor Neurol Neurosci 2000, 17(1):31-38.
2. Banati R.B., Daniel S.E., Blunt S.B. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord 1998, 13(2):221-227.
3. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 2002, 30(1):42-48.
4. Bartmann C., Rohde E., Schallmoser K., Purstner P., Lanzer G., Linkesch W., et al. Two steps to functional mesenchymal stromal cells for clinical application. Transfusion 2007, 47(8):1426-1435.
5. Beck K.D., Valverde J., Alexi T., Poulsen K., Moffat B., Vandlen R.A., et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 1995, 373(6512):339-341.
6. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 1973, 20(4):415-455.
7. Bing G.Y., Lu X., Zheng N.Y., Jin L., Floyd R.A., Kim H.C. Microglia mediated dopaminergic cell death in the substantia nigra: A new animal model for Parkinson's disease. Free Radical Biol. Med. 1998, 25. S44-S44.
8. Bronstein D.M., Perez-Otano I., Sun V., Mullis Sawin S.B., Chan J., Wu G.C., et al. Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures. Brain Res. 1995, 704(1):112-116.
9. Castano A., Herrera A.J., Cano J., Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J. Neurochem. 1998, 70(4):1584-1592.
10. Chen X., Li Y., Wang L., Katakowski M., Zhang L., Chen J., et al. Ischemic rat brain extracts induce human marrow stromal cell growth factor production. Neuropathology 2002, 22(4):275-279.
11. Choi D.Y., Liu M., Hunter R.L., Cass W.A., Pandya J.D., Sullivan P.G., et al. Striatal neuroinflammation promotes Parkinsonism in rats. PLoS ONE 2009, 4(5):e5482.
12. de Meira Santos Lima M., Braga Reksidler A., Marques Zanata S., Bueno Machado H., Tufik S., Vital M.A. Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. Brain Res 2006, 1101(1):117-125.
13. Decressac M., Ulusoy A., Mattsson B., Georgievska B., Romero-Ramos M., Kirik D., et al. GDNF fails to exert neuroprotection in a rat alpha-synuclein model of Parkinson's disease. Brain 2011, 134(Pt 8):2302-2311.
14. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99(10):3838-3843.
15. Digirolamo C.M., Stokes D., Colter D., Phinney D.G., Class R., Prockop D.J. Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Br. J. Haematol. 1999, 107(2):275-281.
16. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003, 9(5):589-595.
17. Hagell P., Brundin P. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J. Neuropathol. Exp. Neurol. 2001, 60(8):741-752.
18. Hoban D.B., Connaughton E., Connaughton C., Hogan G., Thornton C., Mulcahy P., et al. Further characterisation of the LPS model of Parkinson's disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat. Brain Behav. Immun. 2013, 27(1):91-100.
19. Hoban D.B., Newland B., Moloney T.C., Howard L., Pandit A., Dowd E. The reduction in immunogenicity of neurotrophin overexpressing stem cells after intra-striatal transplantation by encapsulation in an in situ gelling collagen hydrogel. Biomaterials 2013, 34(37):9420-9429.
20. Hoffer B.J., Hoffman A., Bowenkamp K., Huettl P., Hudson J., Martin D., et al. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 1994, 182(1):107-111.
21. Hurelbrink C.B., Barker R.A. The potential of GDNF as a treatment for Parkinson's disease. Exp. Neurol. 2004, 185(1):1-6.
22. Jankovic J. Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 2008, 79(4):368-376.
23. Karussis D., Kassis I., Kurkalli B.G., Slavin S. Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases. J. Neurol. Sci. 2008, 265(1-2):131-135.
24. Kearns C.M., Gash D.M. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res. 1995, 672(1-2):104-111.
25. Kirik D., Rosenblad C., Bjorklund A., Mandel R.J. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 2000, 20(12):4686-4700.
26. Kurozumi K., Nakamura K., Tamiya T., Kawano Y., Ishii K., Kobune M., et al. Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. Mol Ther 2005, 11(1):96-104.
27. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006, 59(3):459-466.
28. Lee J.K., Jin H.K., Bae J.S. Bone marrow-derived mesenchymal stem cells reduce brain amyloid-beta deposition and accelerate the activation of microglia in an acutely induced Alzheimer's disease mouse model. Neurosci. Lett. 2009, 450(2):136-141.
29. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260(5111):1130-1132.
30. Lin Y.T., Chern Y., Shen C.K., Wen H.L., Chang Y.C., Li H., et al. Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in Huntington's disease mouse models. PLoS ONE 2011, 6(8):e22924.
31. Mazzini L., Mareschi K., Ferrero I., Vassallo E., Oliveri G., Boccaletti R., et al. Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis. Neurol. Res. 2006, 28(5):523-526.
32. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38(8):1285-1291.
33. McGeer P.L., McGeer E.G. Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis. Assoc. Disord. 1998, 12(Suppl 2):S1-6.
34. Moloney T.C., Dockery P., Windebank A.J., Barry F.P., Howard L., Dowd E. Survival and immunogenicity of mesenchymal stem cells from the green fluorescent protein transgenic rat in the adult rat brain. Neurorehab Neural Rep 2010, 24(7):645-656.
35. Moloney T.C., Rooney G.E., Barry F.P., Howard L., Dowd E. Potential of rat bone marrow-derived mesenchymal stem cells as vehicles for delivery of neurotrophins to the Parkinsonian rat brain. Brain Res. 2010, 1359:33-43.
36. Naoi M., Maruyama W. Cell death of dopamine neurons in aging and Parkinson's disease. Mech. Ageing Dev. 1999, 111(2-3):175-188.
37. Ohtaki H., Ylostalo J.H., Foraker J.E., Robinson A.P., Reger R.L., Shioda S., et al. Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses. Proc. Natl. Acad. Sci. U.S.A. 2008, 105(38):14638-14643.
38. Okabe M., Ikawa M., Kominami K., Nakanishi T., Nishimune Y. 'Green mice' as a source of ubiquitous green cells. FEBS Lett. 1997, 407(3):313-319.
39. Olsson M., Nikkhah G., Bentlage C., Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 1995, 15(5 Pt 2):3863-3875.
40. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2007, Springer Academic Press.
41. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284(5411):143-147.
42. Riederer P., Wuketich S. Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 1976, 38(3-4):277-301.
43. Rooney G.E., McMahon S.S., Ritter T., Garcia Y., Moran C., Madigan N.N., et al. Neurotrophic factor-expressing mesenchymal stem cells survive transplantation into the contused spinal cord without differentiating into neural cells. Tissue Eng. Part A 2009, 15(10):3049-3059.
44. Rooney G.E., Moran C., McMahon S.S., Ritter T., Maenz M., Flugel A., et al. Gene-modified mesenchymal stem cells express functionally active nerve growth factor on an engineered poly lactic glycolic acid (PLGA) substrate. Tissue Eng. Part A 2008, 14(5):681-690.
45. Rosova I., Dao M., Capoccia B., Link D., Nolta J.A. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem cells 2008, 26(8):2173-2182.
46. Rossignol J., Boyer C., Thinard R., Remy S., Dugast A.S., Dubayle D., et al. Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation. J. Cell Mol. Med. 2009, 13(8B):2547-2558.
47. Salawu F., Olokoba A., Danburam A. Current management of Parkinson's disease. Ann Afr Med 2010, 9(2):55-61.
48. Sauer H., Rosenblad C., Bjorklund A. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc. Natl. Acad. Sci. U.S.A. 1995, 92(19):8935-8939.
49. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000, 39(5):777-787.
50. Sherer T.B., Fiske B.K., Svendsen C.N., Lang A.E., Langston J.W. Crossroads in GDNF therapy for Parkinson's disease. Mov Disord 2006, 21(2):136-141.
51. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 2005, 102(2):216-222.
52. Tansey M.G., Goldberg M.S. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2010, 37(3):510-518.
53. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995, 373(6512):335-339.
54. Tzeng S.F., Hsiao H.Y., Mak O.T. Prostaglandins and cyclooxygenases in glial cells during brain inflammation. Curr. Drug Targets Inflamm. Allergy 2005, 4(3):335-340.
55. Yi T., Song S.U. Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch. Pharmacal Res. 2012, 35(2):213-221.
56. Zhang Z., Wang X., Wang S. Isolation and characterization of mesenchymal stem cells derived from bone marrow of patients with Parkinson's disease. In vitro Cell Dev Biol - Animal 2008, 44(5-6):169-177.